Claims

1. A method for treating or preventing infection of feline immunodeficiency virus (FIV) in a feline animal, said method comprising administering to said feline animal an effective amount of azidothymidine (AZT) and another nucleoside analog.

2. The method according to claim 1, wherein said another nucleoside analog is 3TC.

3. The method according to claim 1, wherein said feline animal receives bone marrow transplantation after total body irradiation.

4. The method according to claim 3, wherein the transplanted cells are selected from the group consisting of allogeneic cells and autologous cells.

5. A method for treating or preventing infection of feline immunodeficiency virus (FIV) in a feline animal, said method comprising administering to said feline animal an effective amount of azidothymidine (AZT), another nucleoside analog and an inhibitor of a retroviral protease.

6. The method according to claim 5, wherein said another nucleoside analog is 3TC.

7. The method according to claim 5, wherein said inhibitor of a retroviral protease is selected from the group consisting of HIV protease inhibitors and FIV protease inhibitors.

8. The method accoding to claim 5, wherein said inhibitor of a retroviral protease is designated as HBY-793 and has the structure shown in Figure 4.

9. The method according to claim 5, wherein said another nucleoside analog is 3TC and said inhibitor of a retroviral protease is designated as HBY-793 and has the structure shown in Figure 4.

10. The method according to claim 5, wherein said feline animal receives bone marrow transplantation after total body irradiation.

11. The method according to claim 10, wherein the transplanted cells are selected from the group consisting of allogeneic cells and autologous cells.

12. A kit comprising in one or more containers AZT, another nucleoside analog and an inhibitor of a retroviral protease.

13. The kit according to claim 12, wherein said another nucleoside analog is 3TC.

14. The kit according to claim 12, wherein said inhibitor of a retroviral protease is designated as HBY-793 and has the structure shown in Figure 4.

15. The kit according to claim 12, wherein said another nucleoside analog is 3TC and said inhibitor of a retroviral protease is designated as HBY-793 and has the structure shown in Figure 4.